Table 3.
Clinical and treatment details of the five patients who received concurrent chemoradiotherapy
| Patient | Age | Sex | PS | Site | CT | Cycles (n) | RT dose | Response | Relapse | Alive1 | Survival (mo) |
| 1 | 83 | M | 0 | Low | PE | 4 | 50 Gy in 25 Fr | PR | Local | 1 | 45 |
| 2 | 79 | M | 1 | Low2 | CE | 4 | 45 Gy in 25 Fr | CR | Liver | 1 | 38 |
| 3 | 73 | M | 1 | Low | PE | 3 | 45 Gy in 25 Fr | CR | None | 0 | 92 |
| 4 | 58 | M | 1 | Low | CE | 4 | 50 Gy in 25 Fr | CR | Local3 | 0 | 110 |
| 5 | 79 | M | 0 | Low | CE | 4 | 45 Gy in 25 Fr | PR | Liver | 1 | 40 |
1
1 = Died, 0 = Otherwise.
2
Mixed pathology initially, biopsy confirmed recurrence of squamous cell carcinoma only.
3
New primary with adenocarcinoma; patient had salvage surgery. CE: Cisplatin and etoposide; CT: Chemotherapy; Fr: Fractions; M: Male; PE: Carboplatin and etoposide; PS: Performance status; PR: Partial response; RT: Radiotherapy.